1 min read
Add as a preferred source on Google

Prelude Therapeutics Posts $5.6 Million in Q3 Revenue as Net Loss Narrows

Revenue fell 13% year over year, while net loss narrowed 36% to $12.5 million. The company expects its cash runway to extend into the second quarter of 2028.

A glass hourglass stands beside an unmarked laboratory vial / TokenPost.ai
A glass hourglass stands beside an unmarked laboratory vial / TokenPost.ai

Prelude Therapeutics posted $5.6 million in third-quarter revenue and narrowed its net loss to $12.5 million, while expecting its cash runway to extend into the second quarter of 2028.

Revenue declined 13% from the same quarter a year earlier. Net loss fell 36% to $12.5 million. Net loss per share of common stock, basic and diluted, was $0.12.

Research and development expenses were $14.8 million, down 32% year over year. General and administrative expenses fell 2% to $5.1 million.

Cash, cash equivalents, restricted cash and marketable securities totaled $142.7 million as of Sept. 30, 2026. The company expects its cash runway to extend into the second quarter of 2028.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…